Xenetic Biosciences
XBIO
6 hedge funds and large institutions have $453K invested in Xenetic Biosciences in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.
2.6% less ownership
Funds ownership: 9.99% → 7.38% (-2.6%)
9% less capital invested
Capital invested by funds: $497K → $453K (-$43.6K)
45% less funds holding
Funds holding: 11 → 6 (-5)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$101K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$32.3K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$30K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.91K |
| 5 |
Citigroup
New York
|
-$2.69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $368K | -$101K | -41,069 | -23% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $57.5K | +$19.4K | +7,860 | +58% |
|
3
Vanguard Capital Management
Malvern,
Pennsylvania
| $18K | +$16.6K | +6,731 | New |
|
|
JEST
4
JTC Employer Solutions Trustee
St Helier,
Jersey
| $7K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2.16K | -$7.91K | -3,206 | -80% |
|
|
DWM
6
Darwin Wealth Management
Tampa,
Florida
| $5 | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$32.3K | -14,879 | Closed |
|
|
DS
8
DRW Securities
Chicago,
Illinois
| – | -$30K | -13,824 | Closed |
|
|
9
Citigroup
New York
| – | -$2.69K | -1,241 | Closed |
|
|
AIP
10
Alexis Investment Partners
Montgomery,
Texas
| – | -$54 | -25 | Closed |
|
11
Bank of America
Charlotte,
North Carolina
| – | -$39 | -18 | Closed |
|
12
Morgan Stanley
New York
| – | -$7 | -3 | Closed |
|
XBIO Hedge Fund Activity: Q1 2026 in Review
6 of the 8,169 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2026, worth a combined $453K — down 8.8% from $497K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of XBIO and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, adding an estimated $19.4K. The largest seller was Renaissance Technologies, cutting an estimated $101K.
- 6 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2026, down from 11 in Q4 2025.
- Funds reported $453K of Xenetic Biosciences stock for Q1 2026, down 8.8% quarter-over-quarter.
- 1 fund opened new Xenetic Biosciences positions in Q1 2026 and 6 closed out, a net change of -5 holders.
- The largest Xenetic Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $19.4K added.
- The largest Xenetic Biosciences seller in Q1 2026 was Renaissance Technologies, an estimated $101K sold.
Based on aggregated 13F filings for Q1 2026.